Search

Your search keyword '"Bartenstein, Peter"' showing total 2,457 results

Search Constraints

Start Over You searched for: Author "Bartenstein, Peter" Remove constraint Author: "Bartenstein, Peter"
2,457 results on '"Bartenstein, Peter"'

Search Results

1. [68Ga]Ga-FAPI-46 PET/CT for penile cancer – a feasibility study

2. Assessment of [18F]PI-2620 Tau-PET Quantification via Non-Invasive Automatized Image Derived Input Function

4. Tau accumulation is associated with dopamine deficiency in vivo in four-repeat tauopathies

5. [68 Ga]Ga-FAPI-46 PET/CT for locoregional lymph node staging in urothelial carcinoma of the bladder prior to cystectomy: initial experiences from a pilot analysis

6. Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial.

7. Author Correction: Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE

8. Associations between sex, body mass index and the individual microglial response in Alzheimer’s disease

9. Metabolic network alterations as a supportive biomarker in dementia with Lewy bodies with preserved dopamine transmission

10. Reliability and practicability of PSMA-RADS 1.0 for structured reporting of PSMA-PET/CT scans in prostate cancer patients

13. Individual regional associations between Aβ-, tau- and neurodegeneration (ATN) with microglial activation in patients with primary and secondary tauopathies

15. Towards multicenter β-amyloid PET imaging in mouse models: A triple scanner head-to-head comparison

16. Next-generation PET/CT imaging in meningioma—first clinical experiences using the novel SSTR-targeting peptide [18F]SiTATE

21. Translocator protein (18kDA) (TSPO) marks mesenchymal glioblastoma cell populations characterized by elevated numbers of tumor-associated macrophages

23. Depletion and activation of microglia impact metabolic connectivity of the mouse brain

25. [18F]F-DED PET imaging of reactive astrogliosis in neurodegenerative diseases: preclinical proof of concept and first-in-human data

28. TSPO acts as an immune resistance gene involved in the T cell mediated immune control of glioblastoma

29. Tau deposition patterns are associated with functional connectivity in primary tauopathies

30. Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients

32. Assessment of perfusion deficit with early phases of [18F]PI-2620 tau-PET versus [18F]flutemetamol-amyloid-PET recordings

36. Metabolic patterns on [18F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment

37. Development of PSMA-PET-guided CT-based radiomic signature to predict biochemical recurrence after salvage radiotherapy

38. PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml

39. TSPO PET signal using [18F]GE180 is associated with survival in recurrent gliomas

41. Combination of pre-treatment dynamic [18F]FET PET radiomics and conventional clinical parameters for the survival stratification in patients with IDH-wildtype glioblastoma

42. Additive value of [18F]PI-2620 perfusion imaging in progressive supranuclear palsy and corticobasal syndrome

46. Salvage radiotherapy is effective in patients with PSMA-PET-negative biochemical recurrence- results of a retrospective study

47. Correction to: Next‑generation PET/CT imaging in meningioma—first clinical experiences using the novel SSTR‑targeting peptide [18F]SiTATE

48. The maximum standardized uptake value in patients with recurrent or persistent prostate cancer after radical prostatectomy and PSMA-PET-guided salvage radiotherapy—a multicenter retrospective analysis

49. Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib

Catalog

Books, media, physical & digital resources